December 22, 2023 07:17 AM ESTUpdated 07:31 AM

Bristol Myers bets on neuroscience surge with $14B Karuna cash acquisition

Bristol Myers Squibb will buy CNS drugmaker Karuna Therapeutics for cash in a deal valued at $14 billion, the companies

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bris­tol My­ers bets on neu­ro­science surge with $14B Karuna cash ac­qui­si­tion